January 27, 2015 2:26 PM ET


Company Overview of MacroGenics, Inc.

Company Overview

MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. Its products include Margetuximab, a monoclonal antibody that targets human epidermal growth factor receptor 2-expressing tumors, including breast, gastroesophageal, bladder, and other cancers; MGA271, an Fc-optimized monoclonal antibody for various solid tumor types; MGD006, a humanized dual affinity re-targeting (DART) molecule for the treatment of hematologic cancers; and MGD007, a DART protein to treat colorectal cancer. The company’s products also comprise Teplizumab, a humanized anti-CD3 monoclon...

9640 Medical Center Drive

Rockville, MD 20850

United States

Founded in 2000

166 Employees





Key Executives for MacroGenics, Inc.

Chief Executive Officer
Age: 62
Total Annual Compensation: $456.1K
Chief Financial Officer
Age: 46
Total Annual Compensation: $306.7K
Senior Vice President of Clinical Development
Age: 52
Total Annual Compensation: $148.6K
Compensation as of Fiscal Year 2013.

MacroGenics, Inc. Key Developments

MacroGenics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 07:30 AM

MacroGenics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Scott Koenig, Chief Executive Officer, President and Director.

MacroGenics, Inc. Enters Collaboration and License Agreement with Janssen Biotech, Inc

On December 19, 2014, MacroGenics, Inc. entered into a transaction with Janssen Biotech, Inc. and its affiliate, Johnson & Johnson Innovation JJDC, Inc. comprised of collaboration and license agreement with Janssen. Under the terms of the Collaboration Agreement, Janssen will be fully responsible for developing the company's proprietary product candidate, MGD011, following submission of the investigational new drug application for MGD011 with the U.S. Food and Drug Administration, and is obligated to use commercially reasonable efforts to undertake certain development, regulatory and commercialization activities. MGD011 incorporates the company's proprietary platform for Dual-Affinity Re-Targeting to simultaneously target CD19, a cell-surface protein found on B cells including certain neoplastic B cells, and CD3, a protein found on T cells. This product candidate will be developed for the treatment of various leukemias and lymphomas that express the CD19 protein. MGD011 is currently in pre-clinical development. Under the terms of the Collaboration Agreement, the company will receive a $50 million upfront license fee from Janssen. Assuming successful development and commercialization, the company could receive up to an additional $575 million in clinical, regulatory and commercialization milestone payments as well as double-digit royalties on any global net sales.

MacroGenics, Inc.(NasdaqGS:MGNX) added to NASDAQ Biotechnology Index

MacroGenics, Inc. will be added to the NASDAQ Biotechnology Index.

Similar Private Companies By Industry

Company Name Region
CIMA Biotechnology Inc United States
AuraSense Therapeutics, LLC United States
Coloryte Hungary Rt. United States
Novatrix Biomedical, Inc. United States
Genome Networks, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MacroGenics, Inc., please visit www.macrogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.